Episode Details

Back to Episodes
Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 Inhibitor

Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 Inhibitor

Season 1 Published 2 years, 6 months ago
Description

Dr Aditya Bardia from Massachusetts General Hospital in Boston, Massachusetts, and Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discuss approved and novel treatment approaches for ER-positive metastatic breast cancer that has progressed on prior CDK4/6 inhibitor therapy.

CME information and select publications here.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us